Cubist Pharma strikes deal to buy Adolor for up to $415M

With its share price breaking through to a 52-week high, Cubist Pharmaceuticals ($CBST) has decided to beef up its pipeline of acute care products with a deal to buy Adolor Pharmaceuticals for $190 million in cash and even more than that in backend milestone payments based on the success of a mid-stage drug for opioid-induced constipation. Cubist says the buyout values Adolor at up to $415 million, net cash.

In the acquisition Adolor ($ADLR) shareholders, whose stock was worth $1.92 at Friday's close, will get $4.25 in cash and up to $4.50 more for a CPR based on a set of key milestones. The Exton, PA-based biotech's lead program is ADL5945, an oral treatment that posted positive mid-stage data for opioid-induced constipation back in August. Cubist can now take the therapy into Phase III studies next year, adding that it hopes to find an ex-U.S. partner for the treatment. Adolor also markets Entereg.

Cubist shares slid 4% on the news.

Cubist's immediate challenge will be to make its case that the buyout makes strategic sense. The Lexington, MA-based company has built its reputation on antibiotics, making Adolor's pipeline an add-on in new specialty arenas. And the past two years have been tough on Adolor shareholders, who had to watch as Pfizer dropped out of a $262 million partnership last year and the biotech announced back-to-back layoffs in 2009 and then again in 2010 after sales of Entereg fell below expectations. GlaxoSmithKline recently sold back its rights to Entereg for only $25 million.

"This transaction is an excellent strategic fit for Cubist and the latest milestone in what has been a transformational year for the company," said Cubist CEO Michael Bonney. "Entereg is a first-in-class therapy with strong growth potential, and we believe our experienced sales force and strong commercial platform will realize the potential of this important hospital product. With the addition of ADL5945, Cubist will have a truly outstanding late-stage pipeline with three strong candidates addressing significant markets. We are excited about the acquisition of Adolor and believe it will deliver significant value to our shareholders, hospital customers and patients."

Adolor's $4.50 CPR in the deal is based on the success of ADL5945. Cubist will pay $3 a share if ADL5945 receives FDA approval and another $1.50 per share if ADL5945 wins an EU OK. Both approvals will have to arrive before July 1, 2019.

- read the press release

Suggested Articles

Two weeks after receiving a second dose of Moderna's COVID-19 jab, patients had "robust" levels of neutralizing antibodies against the…

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.